Back to Search
Start Over
Fibroblast Activation Protein Inhibitor Theranostics: Preclinical Combination Treatment.
- Source :
-
PET clinics [PET Clin] 2023 Jul; Vol. 18 (3), pp. 409-418. Date of Electronic Publication: 2023 Mar 27. - Publication Year :
- 2023
-
Abstract
- Fibroblast activation protein (FAP)-radioligand therapy might be effective in some patients without being curative. FAP-radioligands deliver ionizing radiation directly to FAP <superscript>+</superscript> cancer-associated fibroblasts and, in some cancers, to FAP <superscript>+</superscript> tumor cells; in addition, they indirectly irradiate FAP <superscript>-</superscript> cells in tumor tissue via cross-fire and bystander effects. Here, we discuss the potential to improve FAP-radioligand therapy through interfering with DNA damage repair, immunotherapy, and co-targeting cancer-associated fibroblasts. As the molecular and cellular effects of FAP-radioligands on the tumor and its microenvironment have not been investigated yet, we call for future research to close this gap in knowledge, which prevents the development of more effective FAP-radioligand therapies.<br /> (Copyright © 2023 Elsevier Inc. All rights reserved.)
Details
- Language :
- English
- ISSN :
- 1879-9809
- Volume :
- 18
- Issue :
- 3
- Database :
- MEDLINE
- Journal :
- PET clinics
- Publication Type :
- Academic Journal
- Accession number :
- 36990945
- Full Text :
- https://doi.org/10.1016/j.cpet.2023.02.006